UNSPSC 51284023: Demeclocycline hydrochloride

This classification denotes a tetracycline antibiotic with the molecular formula C21H21ClN2O8.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 29O079NTYT, chemically known as 7-chloro-4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,6,10,12,12a-pentahydroxy-1,11-dioxo-2-naphthacenecarboxamide monohydrochloride but more generally known as demeclocycline hydrochloride, which bears US NIH Compound Identifier 5281008.

UNSPSC 51284023 Demeclocycline hydrochloride is a Commodity code that in recent state and local procurement shows minimal alignment with its nominal pharmaceutical scope. The recent opportunities tagged to this code concern naloxone procurement, direct-to-manufacturer prescription programs, fire-rescue medical supplies, and multi-source generic pharmaceuticals—none of which center on demeclocycline hydrochloride, a tetracycline antibiotic used primarily for treatment of inappropriate antidiuretic hormone secretion and hyponatremia. The mismatch suggests either a cataloging error by the issuing bodies or a code applied too broadly to pharmaceutical procurement categories. State and local governments purchasing under related pharmaceutical codes are acquiring emergency response medications (naloxone), emergency medical consumables for rescue operations, and bulk generic pharmaceuticals through cooperative purchasing vehicles, but the available recent activity does not demonstrate focused demand specifically for demeclocycline hydrochloride.

The geographic spread of recent activity includes Florida (Seminole County), Texas (Texas HHS Commission), Florida (City of Tampa), and Minnesota (MMCAP cooperative purchasing covering multiple states including Oregon), though this geographic diversity reflects the broader pharmaceutical and medical-supply procurement landscape rather than concentrated demand for the specific commodity. Representative recent solicitations include Seminole County's IFB60459723LAS (naloxone and drug deactivation systems, due July 26, 2023), the Texas HHS Commission's RFI HHS0017013 for direct-to-manufacturer prescription programs (due April 3, 2026), the City of Tampa's ITB 26P00145 for medical and first aid supplies with an estimated contract value of $700,000.00 (due March 13, 2026), and MMCAP's RFP S1070000015802 for generic multi-source pharmaceuticals (due March 26, 2026). The code shows little relevant recent activity aligned to demeclocycline hydrochloride procurement specifically.